Details of the Drug

General Information of Drug (ID: DMM1RB6)

• Drug Name: GW-328267
• Synonyms: UNII-DJF621DE4F; DJF621DE4F; GW-328267; CHEMBL186113; GW328267; (S)-2-[[6-Amino-9-[4-(2-ethyl-2H-tetrazole-5-yl)-4-de(hydroxymethyl)-1-deoxy-beta-D-ribofuranose-1-yl]-9H-purine-2-yl]amino]-3-phenyl-1-propanol; (S)-2-((6-Amino-9-(4-(2-ethyl-2H-tetrazole-5-yl)-4-de(hydroxymethyl)-1-deoxy-beta-D-ribofuranose-1-yl)-9H-purine-2-yl)amino)-3-phenyl-1-propanol; SCHEMBL1979140; BDBM50150766; J2.047.755E

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Phase 1	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 482.5
  Logarithm of the Partition Coefficient (xlogp); -0.1
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 5
  Hydrogen Bond Acceptor Count (hbondacc); 12
• Chemical Identifiers:
  Formula: C21H26N10O4
  IUPAC Name: (2R,3R,4S,5R)-2-[6-amino-2-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]purin-9-yl]-5-(2-ethyltetrazol-5-yl)oxolane-3,4-diol
  Canonical SMILES: CCN1N=C(N=N1)[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=C(N=C43)N[C@@H](CC5=CC=CC=C5)CO)N)O)O
  InChI: InChI=1S/C21H26N10O4/c1-2-31-28-18(27-29-31)16-14(33)15(34)20(35-16)30-10-23-13-17(22)25-21(26-19(13)30)24-12(9-32)8-11-6-4-3-5-7-11/h3-7,10,12,14-16,20,32-34H,2,8-9H2,1H3,(H3,22,24,25,26)/t12-,14-,15+,16-,20+/m0/s1
  InChIKey: FLBKPDIBGNWXMT-NIQZGXKPSA-N
• Cross-matching ID:
  PubChem CID: 9869857
  CAS Number: 210237-78-8
  TTD ID: D00OAU

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01640990) A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers. U.S. National Institutes of Health.
• [2] ADENOSINE RECEPTORS AS TARGETS FOR THERAPEUTIC INTERVENTION IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE